Pharmaceuticals, Biotechnology and Life Sciences
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for...
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM...
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according...
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to...
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM for reasons that are anything but routine
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon
An 80 million share rights offering authorized in Turku signals a company racing against its own runway
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to artificial intelligence (AI) and automation — not just general cost-cutting. The biggest recent example comes from fintech firm Block Inc., which announced plans to cut over 4,000 jobs — roughly 40 % of its workforce — as AI tools reshape how it builds and runs its business, according to multiple news reports. What about pharma?
A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.
